髓系免疫抑制表型定义肝细胞癌对阿替利珠单抗联合贝伐珠单抗的原发性难治
本研究分析1,296例一线接受阿替利珠单抗联合贝伐珠单抗(A+B)的肝细胞癌患者,并在IMbrave150和GO30140试验的645例参与者中验证。按SITC标准定义原发性难治(PRef),发现其与更差的总生存相关,且以全身炎症、髓系浸润和T细胞耗竭为特征,IFN-γ签名下调和NLR≥3是PRef最强贡献因素。
要点
- 按SITC标准,约40%的A+B治疗患者表现为原发性难治,与更差的总生存相关。
- 原发性难治肿瘤以髓系免疫抑制、CD163+巨噬细胞浸润和Treg/Teff比值升高为特征。
- IFN-γ签名下调和NLR≥3是原发性难治的最强贡献因素。
核心结论
- A+B原发性难治是一种以全身炎症、髓系浸润和T细胞耗竭为特征的独特生物学实体。
- 靶向髓系介导的免疫抑制,尤其在IFN-γ签名低表达和NLR升高的患者中,可能增强A+B的应答。
研究设计与样本
- 多队列转化研究:分析1,296例一线A+B治疗的肝细胞癌患者(AB-real),并在645例IMbrave150和GO30140试验参与者中验证。
- 按SITC标准定义原发性难治,对治疗前肿瘤组织进行多参数分析,包括机器学习量化肿瘤浸润淋巴细胞、成像质谱流式和RNA测序。
- 另用两个独立队列通过单细胞RNA测序(n=20)和成像质谱流式(n=16)细化肿瘤微环境特征。
- 采用条件推断树分析提供原发性难治决定因素的层次结构。
主要发现
- 在677例AB-real患者和378例可评估的试验参与者中,原发性难治与更差的中位总生存相关(AB-real:7.3 vs. 31.5个月,p <0.001;试验:10.8 vs. 未达到,p <0.001)。
- 原发性难治患者基线全身炎症更高(中性粒细胞与淋巴细胞比值[NLR] ≥3),肿瘤微环境富集CD163+肿瘤相关巨噬细胞和血管性癌症相关成纤维细胞,Treg/Teff细胞比值更高。
- 肿瘤组织RNA测序证实原发性难治样本内在免疫原性更低,伴髓系浸润升高。
- 条件推断树分析确定IFN-γ签名下调和NLR ≥3是原发性难治的最强贡献因素。
关键数值与推荐
- 原发性难治按SITC(癌症免疫治疗学会)标准定义,并在肝细胞癌中首次临床验证。
- 约40%的患者按SITC标准表现为原发性难治。
- 基线NLR ≥3与原发性难治相关。
临床怎么用
- 对拟接受一线A+B治疗的肝细胞癌患者,可评估基线NLR和IFN-γ签名以识别原发性难治高风险。
- 针对髓系介导的免疫抑制,尤其在IFN-γ签名低表达和NLR升高患者中,可能作为克服原发性耐药的合理联合策略。
- 上述发现可为生物标志物分层试验和合理联合策略的设计提供生物学框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma, primary refractoriness (PRef), characterised by early progression or short-lived disease stabilisation following treatment, remains a significant challenge. METHODS: We analysed 1,296 patients with hepatocellular carcinoma treated with frontline A+B (AB-real) and validated findings in 645 trial participants recruited to IMbrave150 and GO30140. PRef was defined by SITC (Society for the Immunotherapy of Cancer) criteria. We performed a multi-parametric analysis of pre-treatment tumour tissue, including machine learning-based quantification of tumour-infiltrating lymphocytes, imaging mass cytometry and RNA sequencing (RNA-seq) to evaluate differences in the tumour microenvironment (TME) of patients with PRef vs. responders. Two independent cohorts were further used to refine the TME characterisation through single-cell RNA-seq (n = 20) and imaging mass cytometry (n = 16). We employed conditional inference tree analyses to provide a hierarchical organisation of PRef determinants. RESULTS: Among 677 AB-real patients and 378 trial participants evaluable by SITC criteria, PRef was associated with inferior median overall survival compared to response (AB-real: 7.3 vs. 31.5 months, p <0.001; Trials: 10.8 vs. not reached, p <0.001). Patients with PRef exhibited higher baseline systemic inflammation (neutrophil-to-lymphocyte ratio [NLR] ≥3), a distinctly immunosuppressive TME enriched in CD163+ tumour-associated macrophages and vascular cancer-associated fibroblasts, a higher Treg/Teff cell ratio, and pro-tumour supportive cellular interactions. RNA-seq of tumour tissue confirmed lower intrinsic immunogenicity in PRef samples with elevated myeloid infiltration. Conditional inference tree analysis identified IFN-γ signature downregulation combined with NLR ≥3 as the strongest contributor of PRef. CONCLUSIONS: PRef to A+B identifies a distinct biological entity characterised by unopposed systemic inflammation, myeloid infiltration, and T-cell depletion. Targeting myeloid-mediated immunosuppression, particularly in patients with low IFN-γ signature expression and elevated NLR might enhance responsiveness to A+B. IMPACT AND IMPLICATIONS: Atezolizumab plus bevacizumab represents the standard first-line treatment for unresectable hepatocellular carcinoma, yet the biological basis of early treatment failure remains poorly understood. In this multi-cohort translational study, we show that approximately 40% of patients exhibit primary refractoriness according to SITC criteria - clinically validated here for the first time in hepatocellular carcinoma - and identify a distinct immuno-molecular profile of primary refractory tumours characterised by IFN-γ pathway repression, unfavourable myeloid polarisation, and a distinct spatial immune architecture. These findings provide a biological framework that may inform the design of biomarker-stratified trials and rational combination strategies to overcome primary resistance to first-line immunotherapy.
引用
- Lombardi P, Ramon-Gil E, Raja RQ, et al. A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma. J Hepatol. 2026. PMID: 42297215. doi:10.1016/j.jhep.2026.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。